Westfield Capital Management Co. LP Boosts Stake in Glaukos Corporation (NYSE:GKOS)

Westfield Capital Management Co. LP grew its position in Glaukos Corporation (NYSE:GKOS - Free Report) by 34.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,084,184 shares of the medical instruments supplier's stock after acquiring an additional 277,033 shares during the period. Westfield Capital Management Co. LP owned about 1.90% of Glaukos worth $106,705,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. grew its position in shares of Glaukos by 4.9% in the 4th quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock valued at $218,708,000 after buying an additional 68,310 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Glaukos by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock valued at $179,555,000 after buying an additional 25,199 shares in the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in shares of Glaukos by 25.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 825,276 shares of the medical instruments supplier's stock worth $123,742,000 after purchasing an additional 166,677 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Glaukos by 7.4% during the fourth quarter. Northern Trust Corp now owns 578,673 shares of the medical instruments supplier's stock valued at $86,766,000 after buying an additional 40,052 shares during the period. Finally, Principal Financial Group Inc. increased its position in shares of Glaukos by 21.8% in the first quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock worth $32,187,000 after acquiring an additional 58,502 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Stock Up 0.8%

Shares of Glaukos stock traded up $0.66 on Tuesday, hitting $88.16. The company had a trading volume of 1,764,464 shares, compared to its average volume of 1,171,363. The firm has a market capitalization of $5.04 billion, a P/E ratio of -53.43 and a beta of 0.78. Glaukos Corporation has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The stock has a 50-day moving average of $97.82 and a 200-day moving average of $107.39.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.52) earnings per share. Research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on GKOS shares. Piper Sandler cut their price target on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Morgan Stanley lowered their price objective on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Needham & Company LLC cut their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Mizuho set a $130.00 price target on shares of Glaukos in a research report on Thursday, July 31st. Finally, BTIG Research reiterated a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.